Survival and Complications After Neoadjuvant Chemotherapy or Chemoradiotherapy for Esophageal Cancer: A Meta-Analysis

作者：Jinmin Han, Zhongtang Wang, Chengxin Liu · 发表于：Future Oncology · 年份：2021 · DOI：10.2217/fon-2021-0021 · 被引用次数：52 · 研究领域：Esophageal Cancer Research and Treatment、Gastric Cancer Management and Outcomes、Esophageal and GI Pathology

Objectives: To identify the effective approach between neoadjuvant chemotherapy (NCT) and chemoradiotherapy (NCRT) by comparing patient survival and complications. Methods: A systematic literature search of articles published between January 1980 and October 2020 was conducted. Data were extracted and analyzed with STATA 12.0. Results: Five randomized trials and 15 retrospective studies, including 4529 patients (NCT: 2035; NCRT: 2494), were enrolled. Compared with NCT, NCRT provided a higher 3-year survival benefit, higher R0 resection and pathological complete response rates and lower local recurrence and distant metastasis rates, but no increase in 5-year survival. Perioperative mortality and cardiovascular complications were more common in patients with adenocarcinoma. Conclusions: Further studies should concentrate on identifying the optimal neoadjuvant approach and suitable beneficiaries.